• Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends
Close Search
00
GBAF LogoGBAF Logo
  • Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends
GBAF Logo
  • Top Stories
  • Interviews
  • Business
  • Finance
  • Banking
  • Technology
  • Investing
  • Trading
  • Videos
  • Awards
  • Magazines
  • Headlines
  • Trends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking & Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Wealth
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2025 GBAF Publications Ltd - All Rights Reserved.

    ;
    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Top Stories

    Posted By maria gbaf

    Posted on December 2, 2021

    Featured image for article about Top Stories

    By Michael Holden

    LONDON (Reuters) – Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.

    The deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.

    “These new deals will future proof the Great British vaccination effort – which has so far delivered more than 115 million first, second and booster jabs across the UK – and will ensure we can protect even more people in the years ahead,” health minister Sajid Javid said.

    So far, nearly 51 million people in Britain have received their first COVID vaccine – almost 89% of the population aged over 12, more than 46 million have had two doses, and some 18.6 million have received a booster shot.

    On Tuesday Prime Minister Boris Johnson announced a new target this week to offer all adults a vaccine booster by the end of January, which means speeding up the rollout by an extra million doses a week.

    So far 32 cases of the heavily mutated Omicron variant, which it is feared could be more transmissible, have been identified in Britain which has sparked the government into ramping out the vaccine programme.

    Britain has made it mandatory to wear masks on public transport and shops, but Johnson and his ministers hope the booster programme will mean there will be no need for further restrictions or measures to curb social gatherings.

    The contracts for the additional vaccines come on top of an order for 35 million Pfizer shots made in August for the second half of next year, and for 60 million Novavax and 7.5 million GlaxoSmithKline (GSK)/Sanofi doses which are due in 2022 but are yet to be approved by the British regulator.

    Wealthy countries have been accused of not doing enough to distribute stockpiles of vaccines to poorer nations, and the British government said it remained committed to donating 100 million doses by the middle of 2022, saying 30 million would be donated by the end of this year.

    Johnson will also on Thursday host a roundtable of leaders from major pharmaceutical firms including AstraZeneca, GSK and Pfizer to discuss preparations to deal with any future pandemics.

    (Reporting by Michael Holden; editing by David Evans)

    By Michael Holden

    LONDON (Reuters) – Britain said on Wednesday it had agreed deals to buy 114 million more Pfizer/BioNTech and Moderna COVID-19 vaccine shots, saying it had sped up signing the new contracts in light of the emergence of the new Omicron variant.

    The deal involves an additional 60 million Moderna shots and 54 million Pfizer doses for next year and 2023, and will also include access to any modified vaccinations if they are needed to combat the Omicron strain or any other variant, the British health ministry said.

    “These new deals will future proof the Great British vaccination effort – which has so far delivered more than 115 million first, second and booster jabs across the UK – and will ensure we can protect even more people in the years ahead,” health minister Sajid Javid said.

    So far, nearly 51 million people in Britain have received their first COVID vaccine – almost 89% of the population aged over 12, more than 46 million have had two doses, and some 18.6 million have received a booster shot.

    On Tuesday Prime Minister Boris Johnson announced a new target this week to offer all adults a vaccine booster by the end of January, which means speeding up the rollout by an extra million doses a week.

    So far 32 cases of the heavily mutated Omicron variant, which it is feared could be more transmissible, have been identified in Britain which has sparked the government into ramping out the vaccine programme.

    Britain has made it mandatory to wear masks on public transport and shops, but Johnson and his ministers hope the booster programme will mean there will be no need for further restrictions or measures to curb social gatherings.

    The contracts for the additional vaccines come on top of an order for 35 million Pfizer shots made in August for the second half of next year, and for 60 million Novavax and 7.5 million GlaxoSmithKline (GSK)/Sanofi doses which are due in 2022 but are yet to be approved by the British regulator.

    Wealthy countries have been accused of not doing enough to distribute stockpiles of vaccines to poorer nations, and the British government said it remained committed to donating 100 million doses by the middle of 2022, saying 30 million would be donated by the end of this year.

    Johnson will also on Thursday host a roundtable of leaders from major pharmaceutical firms including AstraZeneca, GSK and Pfizer to discuss preparations to deal with any future pandemics.

    (Reporting by Michael Holden; editing by David Evans)

    Recommended for you

    • Thumbnail for recommended article

    • Thumbnail for recommended article

    • Thumbnail for recommended article

    Why waste money on news and opinions when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe